



Mukka Proteins Limited



ISO 22000
Certified Company



ISO 9001 : 2015
Certified Company

Date: 14-02-2025

National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex,
Bandra East, Mumbai-400051
Scrip Code: MUKKA

BSE Limited
Listing Department
Dalal Street,
Mumbai-400001
Scrip Code: 544135

Dear Sir/Madam,

Subject: Report of the Monitoring Agency with respect to utilization of proceeds of the Initial Public Offering (IPO), for the quarter ended 31st December 2024.

Pursuant to Regulation 32(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Regulation 41(4) of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, we are enclosing herewith the Monitoring Agency Report dated 13th February 2025, issued by ICRA Limited, for the quarter ended 31st December 2024, in respect of utilization of proceeds of the IPO of the Company.

This is for your information and records.

Thanking you,

For **Mukka Proteins Limited**

Mehaboobsab Mahmadgous Chalyal
Company Secretary & Compliance Officer

Encl: as above.

Mfrs. & Exporters of Steam Dried Fish Meal, Fish Oil & Fish Soluble Paste

Factory : D. No. 14-161 to 164, Sasihithlu Road, Mukka, Mangaluru - 575021. Karnataka, India

Office : Mukka Corporate House, Door No. 18-2-16/4, First Cross, NG Road, Attavara, Mangaluru, Dakshina Kannada, Karnataka, India - 575001

☎ : (O) +91 824 2420772, 2442889, 4252889 | Fax : +91 824 2426405

E-mail : info@mukkaproteins.com - Website : www.mukkaproteins.com - CIN : L05004KA2010PLC055771

Date: February 13, 2025

Mr. K. Mohammed Altaf

CFO

Mukka Proteins Limited

Mukka Corporate House,

Door No: 18-2-16/4,

First Cross, N.G. Road, Attavara,

Mangaluru 575001.

Karnataka, India.

Dear Sir,

Re: Final Monitoring Agency report of Mukka Proteins Limited for Q3 FY2025

Please refer to agreement dated December 16, 2023, appointing ICRA Limited as the Monitoring Agency (MA) for Mukka Proteins Limited's IPO Issue.

After due consideration, ICRA has prepared the attached final Monitoring Agency report as per SEBI (Issue of Capital and Disclosure Requirements) Regulations for Q3 FY2025.

Please note that the Monitoring Agency report does not constitute a commentary on the quality of the objects of the issue, appropriateness or reasonableness of costs or spending by Mukka Proteins Limited against any objects / heads or assurance on outcome of such spending.

We thank you for your kind cooperation extended during the course of Q3 FY2025. Should you require any clarification, please do not hesitate to get in touch with us.

We look forward to your communication and assure you of our best services.

With kind regards

For ICRA Limited

**PARUL
GOYAL
NARAN
G**

Digitally signed

by PARUL

GOYAL NARANG

Date: 2025.02.13

12:35:52 +05'30'

Parul Goyal Narang

Vice President & Head- Process Excellence

Parul.goyal@icraindia.com

MONITORING AGENCY REPORT**Name of the Issuer:** Mukka Proteins Limited**For quarter ended:** December 31, 2024**Name of the Monitoring Agency (MA):** ICRA Limited**(a) Deviation from the objects of the issue:**

No deviation - the utilization of the issuance proceeds is in line with the objects of the issue.

(b) Range of deviation:

Not Applicable

Declaration:

We declare that this report provides an objective view of the utilization of the issue proceeds in relation to the objects of the issue based on the information provided by the Issuer and information obtained from sources believed by it to be accurate and reliable. The MA does not perform an audit and undertakes no independent verification of any information/ certifications/ statements it receives. This Report is not intended to create any legally binding obligations on the MA which accepts no responsibility, whatsoever, for loss or damage from the use of the said information. The views and opinions expressed herein do not constitute the opinion of MA to deal in any security of the Issuer in any manner whatsoever. Nothing mentioned in this report is intended to or should be construed as creating a fiduciary relationship between the MA and any issuer or between the agency and any user of this report. The MA and its affiliates also do not act as an expert as defined under Section 2(38) of the Companies Act, 2013. The MA or its affiliates may have credit rating or other commercial transactions with the entity to which the report pertains and may receive separate compensation for its ratings and certain credit related analyses. We confirm that we do not perceive any conflict of interest in such relationship/ interest while monitoring and reporting the utilization of the issue proceeds by the issuer. We have submitted the report herewith in line with the format prescribed by SEBI, capturing our comments, where applicable. There are certain sections of the report under the title "Comments of the Board of Directors", that shall be captured by the Issuer's Management / Audit Committee of the Board of Directors subsequent to the MA submitting their report to the issuer and before dissemination of the report through stock exchanges. These sections have not been reviewed by the MA, and the MA takes no responsibility for such comments of the issuer's Management/Board.

Signature:

PARUL
GOYAL
NARANG

Digitally signed
by PARUL
GOYAL NARANG
Date: 2025.02.13
12:32:26 +05'30'

Parul Goyal Narang

Vice President & Head- Process Excellence

Analyst: Subhechha Banerjee

Quality Analyst: Parul Goyal Narang

1. Issuer Details**Name of the Issuer:** Mukka Proteins Limited**Name(s) of the promoters:**

Promoters
Kalandan Mohammed Haris
Kalandan Mohammad Arif
Kalandan Mohammed Althaf

Source: BSE

Industry/ sector to which it belongs:

- Food Products - Seafood

2. Issue Details**Issue Period:** Opening date- February 29, 2024

Closing date- March 04, 2024

Type of Issue: Initial Public Offer**Type of specified securities:** Equity shares**IPO Grading, if any:** No credit rating agency registered with SEBI has been appointed in respect of obtaining grading for the offer.**Issue Size (Rs. Crore):** INR 224.000 crores (Up to 80,000,000 equity shares of INR 28.000 each at a price including premium of INR 27.000 each)**With OFS portion:** Not Applicable.**Excluding OFS portion:** Not Applicable**Net proceeds as per the Offer Letter:** INR 185.808 Crore* (Excluding Issue Related Expenses)

**Note: The estimated IPO expenses as per the prospectus were Rs.38.192 crores, while the Actual IPO expenses have been higher by INR 7.428 crores and stood at INR 45.62 crores.*

The estimated GCP utilization was capped at INR 50.910 crore in the in Q4 FY24 due to excess issuer related expenses of Rs. 4.898 crores. However, in Q1 FY25 the overall variance in IPO expenses of INR 7.428 crore including Rs. 2.53 of Issue related expenditure incurred in Q1 2025 has been absorbed into general corporate purpose.

3. Details of the arrangement made to ensure the monitoring of issue proceeds.

Particulars	Reply	Source of information, certifications considered by the Monitoring Agency for the preparation of report	Comments of the Monitoring Agency	Comments of the Issuer's Board of Directors
Whether all utilization is as per the disclosures in the Offer Document?	Yes	-Peer reviewed CA certificate -Confirmation from management -Bank statement of the proceeds account	No comments	
Whether shareholder approval has been obtained in case of material deviations [#] from expenditures disclosed in the Offer Document?	Not Applicable	As confirmed by the Issuer's management	No comments	
Whether the means of finance for the disclosed objects of the issue has changed?	No	As confirmed by the Issuer's management	No comments	
Is there any major deviation observed over the earlier monitoring agency reports?	No	As confirmed by the Issuer's management	No comments	
Whether all Government/ statutory approvals related to the object(s) have been obtained?	Not Applicable	As confirmed by the Issuer's management	No comments	
Whether all arrangements pertaining to technical assistance/ collaboration are in operation?	Not Applicable	As confirmed by the Issuer's management	No comments	
Are there any favorable events improving the viability of these object(s)?	No	As confirmed by the Issuer's management	As understood from the Issuer's management	
Are there any unfavorable events affecting the viability of the object(s)?	No	As confirmed by the Issuer's management	As understood from the Issuer's management	
Is there any other relevant information that may materially affect the decision making of the investors?	No	As confirmed by the Issuer's management	As understood from the Issuer's management	

[#] Where material deviation is defined to mean:

(a) Deviation in the objects or purposes for which the funds had been raised.

(b) Deviation in the amount of funds utilized by more than 10% of the amount specified in the offer document.

4. Details of the object(s) to be monitored.
(i) Cost of object(s)

S.N.	Item Head	Source of information, certifications considered by the Monitoring Agency for the preparation of report	Original cost (as per the offer document) [Rs. Crore]	Revised cost [Rs. Crore]	Comments of the Monitoring Agency	Comments of the Issuer's Board of Directors		
						Reason for cost revision	Proposed financing option	Particulars of firm arrangements made
1	Funding working capital requirements of Company	Prospectus	120.000	-	No Comments			
2	Investment in Associate, viz. Ento Proteins Private Limited, for funding its working capital requirements	Prospectus	10.000	-	No Comments			
3	General corporate purposes	Prospectus	55.808	-	No comments			
Total			185.808	-				

(ii) Progress in the object(s)

S.N.	Item Head*	Source of information, certifications considered by the Monitoring Agency for the preparation of report	Amount as proposed in the offer document [Rs. Crore]	Amount utilized [Rs. Crore]			Total unutilized amount [Rs. Crore]	Comments of the Monitoring Agency	Comments of the Issuer's Board of Directors	
				As at the beginning of the quarter	During the quarter	At the end of the quarter			Reasons for idle funds	Proposed course of action
1	Funding working capital requirements of our Company	-Peer Reviewed CA Certificate -Bank statement of the proceeds account -Prospectus	120.000	120.000	-	120.000	Nil	No comments		
2	Investment in our Associate, viz. Ento Proteins Private Limited, for funding its working capital requirements	Same as above	10.000	10.000	-	10.000	Nil	No comments		
3	General corporate purposes [^]	Same as above	55.808	55.698	0.110	55.808	Nil	No Comments		
	Total		185.808	178.356	0.110	185.808	Nil			

[^] The estimated IPO expenses as per the prospectus were Rs.38.192 crores, while the Actual IPO expenses have been higher by INR 7.428 crores and stood at INR 45.62 crores.

The estimated GCP utilization was capped at INR 50.910 crore in the in Q4 FY24 due to excess issuer related expenses of Rs. 4.898 crores. However, in Q1 FY25 the overall variance in IPO expenses of INR 7.428 crore including Rs. 2.53 of issue related expenditure incurred in Q1 2025 has been absorbed into general corporate purpose.

(iii) Deployment of unutilized proceeds

S.N.	Type of instrument and name of the entity invested in	Amount invested [Rs. Crore]	Maturity date	Earning [Rs. Crore]	Return on Investment [%]	Market Value as at the end of quarter [Rs. Crore]
<i>Nil</i>						

(iv) Delay in the implementation of the object(s)

Object(s)	Completion date		Delay [Number of days or months]	Comments of the Issuer's Board of Directors	
	As per the offer document	Actual ^A		Reason for delay	Proposed course of action
<i>Funding working capital requirements of our Company</i>	<i>Fiscal 2025</i>	<i>On Schedule</i>	<i>NA</i>		
<i>Investment in our Associate, viz. Ento Proteins Private Limited, for funding its working capital requirements</i>	<i>Fiscal 2025</i>	<i>On Schedule</i>	<i>NA</i>		
<i>General corporate purposes</i>	<i>Fiscal 2025</i>	<i>On Schedule</i>	<i>NA</i>		

Source: Prospectus

5. Details of utilization of proceeds stated as General Corporate Purpose (GCP) amount in the offer document

S.N.	Item Head	Amount [Rs. Crore]	Source of information, certifications considered by the Monitoring Agency for the preparation of report	Comments of the Monitoring Agency	Comments of the Issuer's Board of Directors
1	Repayment of working capital demand loan – Q4FY24	10.000**	-Peer reviewed CA Certificate -Bank Statements	No comments	
2	Other factory and Miscellaneous exp, part repayment of short-term loan – Q4FY24	8.000**	-Peer reviewed CA Certificate -Bank Statements	No comments	
3	Repayment of Bill discounting facilities – Q1FY25	21.582^	-Peer reviewed CA Certificate -Bank Statements	No comments	
4	Statutory Payments – Q1FY25	0.983^	-Peer reviewed CA Certificate -Bank Statements	No comments	
5	Other factory & miscellaneous exp, part payment of short-term loan – Q1FY25	7.705^	-Peer reviewed CA Certificate -Bank Statements	No comments	
6	Payment of IPO Expenses	7.428*	-Peer reviewed CA Certificate -Bank Statements	No comments	
7	Payment to Creditors – Q3FY25	0.110	-Peer reviewed CA Certificate -Bank Statements	No comments	
	Total	55.808			

* Including the amount incurred towards Issue Related expenses in Q4 FY2024

** The said utilization was made in Q4 FY2024

^ The said utilization was made in Q1 FY2025